Pharmacological inhibition of platelet collagen interaction is a promising therapeutic strategy to treat intra-vascular thrombosis. S007-867 is a novel synthetic inhibitor of collagen-induced platelet aggregation. It has shown better antithrombotic protection than aspirin and clopidogrel with minimal bleeding tendency in mice. The present study is aimed to systematically investigate the antithrombotic efficacy of S007-867 in comparison to aspirin and clopidogrel in vivo and to delineate its mechanism of action in vitro. Aspirin, clopidogrel, and S007-867 significantly reduced thrombus weight in arterio-venous (AV) shunt model in rats. In mice, following ferric chloride induced thrombosis in either carotid or mesenteric artery; S007-867 significantly prolonged the vessel occlusion time (1.2-fold) and maintained a sustained blood flow velocity for >30 min. Comparatively, clopidogrel showed significant prolongation in TTO (1.3-fold) while aspirin remained ineffective. Both S007-867 and aspirin did not alter bleeding time in either kidney or spleen injury models, and thus maintained hemostasis, while clopidogrel showed significant increase in spleen bleeding time (1.7-fold). The coagulation parameters namely thrombin time, prothrombin time or activated partial thromboplastin time remained unaffected even at high concentration of S007-867 (300 mM), thus implying its antithrombotic effect to be primarily platelet mediated. S007-867 significantly inhibited collagen-mediated platelet adhesion and aggregation in mice ex-vivo. Moreover, when blood was perfused over a highly thrombogenic combination of collagen mimicking peptides like CRP-GFOGER-VWF-III, S007-867 significantly reduced total thrombus volume or ZV 50 (53.4 ± 5.7%). Mechanistically, S007-867 (10-300 lM) inhibited collagen-induced ATP release, thromboxane A 2 (TxA 2 ) generation, intra-platelet [Ca +2 ] flux and global tyrosine phosphorylation including PLCc2. Collectively the present study highlights that S007-867 is a novel synthetic inhibitor of collagen induced platelet activation, that effectively maintains blood flow velocity and delays vascular occlusion. It inhibits thrombogenesis without compromising hemostasis. Therefore, S007-867 may be further developed for the treatment of thrombotic disorders in clinical settings.
a b s t r a c t
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Introduction
Arterial thrombosis is the root cause of acute myocardial infarction and cerebral stroke in which platelets play a leading role [1] . Although the present antithrombotic strategy has been clinically successful [2] , it suffers from major limitations such as enhanced incidence of bleeding and recurrence of thrombotic episodes. Additionally, the inconvenient intravenous route of administration of drugs like integrin a IIb b 3 antagonists coupled with their inadequacy to cure cerebral stroke warrants development of new antithrombotic drugs.
Platelet collagen receptors play a critical role in the pathogenesis of athero-thrombosis [3, 4] , while their absence produces only a modest prolongation in bleeding time. It is noteworthy that collagen is abundant in atherosclerotic plaques where it contributes to lesion growth and arterial narrowing. the over-expression of collagen receptors is correlated with the incidence of stroke and myocardial infarction [5, 6] . GPVI deficient mice subjected to transient middle cerebral artery occlusion showed significant protection with respect to reduction in brain infarct along with minimal bleeding phenotype [7] . It is anticipated that inhibitors blocking platelet-collagen interaction may provide better efficacy and safety than existing drugs. However, at present not a single inhibitor-synthetic or natural -targeting platelet collagen interaction is in clinical use.
A number of unique strategies of collagen antagonism have been developed such as recombinant fusion proteins (Revacept), small peptides, proteins isolated from natural products and recombinant monoclonal antibodies. Few promising entities are in different stages of pre-clinical and clinical testing. Revacept [8] , is presently undergoing Phase III trial on patients with symptomatic carotid artery stenosis, TIAs, or stroke [9] . Among small molecule inhibitors, Losartan inhibits platelet activation by blocking GPVI clustering [10] . Similarly, caffeic acid phenethyl ester (CAPE) [11] , its analogue CAPE-NO 2 [12] , Honokiol and Hinokitiol [13] [14] [15] are bioactive compounds derived from plant or other natural sources and are known to inhibit collagen-induced platelet activation. Recently, a synthetic platelet GPVI antagonist S002-333, belonging to a new class of 2,3-disubstituted tetrahydropyridoindoles, showed promising antithrombotic efficacy in animal and in vitro models [16] . Additionally, a number of alternative strategies targeting the regulation of expression and functions of collagen receptors have also been proposed. Few such targets include collagen induced signalling (SYK inhibitors) [17, 18] , GPVI dimerization and clustering [19] , or receptor shedding from the platelet surface [20] . However, there is still a wide gap between efficacy and safety of such anti-platelet compounds. An early clinical trial regarding proof of principle/concept may assist in screening potent and efficacious molecules.
In a previous study, we identified a novel synthetic anti-platelet compound S007-867 (tert-butyl ((S)-1-(4-methyl-benyl)-5-oxopyr rolidine-2-carbonyl) piperidin-3-yl) methylcarbamate), that showed better antithrombotic activity than aspirin and clopidogrel with minimal bleeding tendency in mice [21, 22] . The subsequent pharmacokinetic studies revealed its rapid absorption and fast onset of action in mice after oral administration [22] [23] [24] . Although our preliminary study reported that S007-867 inhibits collagen induced platelet aggregation (IC 50 = 6 mM) [21, 22] , the efficacy of compound in different thrombosis models, coagulation parameters, platelet functions and underlying signalling mechanisms is still not known.
Therefore, the present study is aimed to systematically elucidate a detailed pharmacological profile of S007-867 in mice, rats and human platelets, so as to advance it for drug development and clinical use. We evaluated antithrombotic efficacy of S007-867 in different animal models of thrombosis in comparison to aspirin and clopidogrel. Furthermore, using human blood we have also delineated that its antithrombotic mechanism is platelet mediated without involving coagulation cascade. S007-867 inhibits collagen induced platelet activation and deregulates subsequent signalling mechanisms namely platelet aggregation, ATP release from granules, thromboxane A 2 generation via cyclooxygenase 1, intra-platelet calcium mobilization and tyrosine phosphorylation of multiple proteins including PLCc2.
Materials and methods

Chemicals and reagents
S007-867 (purity !99%) was synthesized and characterized in the Medicinal and Process Chemistry Division, CSIR-Central Drug Research Institute (CSIR-CDRI), as described previously [22] . Aspirin was purchased from Sigma, USA and clopidogrel from Matrix Laboratories Limited, India. Adenosine Diphosphate (ADP), Thrombin, Arachidonic Acid, Collagen (fibrillar equine tendon type I) and Chronolume reagent were purchased from Chronolog corp (Pennsylvania, USA). The collagen related peptide (CRP) and other collagen-mimetic peptides were synthesized in Richard W Farndale's laboratory at Department of Biochemistry, Cambridge University, Cambridge, UK, as described earlier [25] . 
Animal experiments
Swiss albino mice (male, 25-30 g) and Sprague Dawley rats (male, 150-160 g) were obtained from Laboratory Animal Division, CSIR-CDRI. Animals were maintained at ambient temperature (23-25°C), relative humidity of 50-70% and 12 h/12 h light/dark cycle. All the experimental protocols were approved by Institutional Animal Ethics Committee, CSIR-CDRI. All the animals were divided into individual groups each consisting of 6-8 animals. Urethane (1.25 g/kg, i.p.) was used to anaesthetize rats for AV shunt model. A mixture of ketamine (80 mg/kg) and xylazine (20 mg/kg) (i.p.) was administered to mice prior to surgery for FeCl 3 induced thrombosis and injury models. S007-867 was administered orally 1 h prior to experiment, and the oral dose was formulated in 0.5% carboxymethyl cellulose suspension, that was also used as vehicle.
Arterio-venous shunt model in rats
A cervical incision was made and carotid artery and its contra lateral jugular vein was exposed. Two 7-cm siliconized polyethylene tubes (0.5/1.0 mm inner/outer diameter) were linked to a central 6 cm silicon tube (1.0/1.5 mm, inner/outer diameter) containing a 5 cm silk thread (pre-weighed) and were filled with saline. The shunt assembly was cannulated between the jugular vein and contra-lateral carotid artery and blood was allowed to circulate through the shunt. Blood flow through the shunt was maintained for 10 min, subsequently the central part of the shunt was removed and silk thread with thrombus was weighed. The thrombus adhered/deposited on thread was calculated by subtracting the wet weight of the silk thread [26] .
FeCl 3 -induced thrombosis in mice carotid artery using Doppler probe
The carotid artery was dissected and a pulsed Doppler probe (DBF-120A-CPx, CBI-8000, Crystal Biotech, USA) was attached to record the blood flow and patency (BIOPAC Systems, USA) as described previously [27] . After stabilizing for 20 min, Whatman paper discs (0.5 Â 1 mm) pre-soaked in 10% FeCl 3 solution were placed on exposed artery for 5 min. Blood flow was recorded until complete cessation, and represent time to occlusion (TTO). If the blood flow did not cease within 120 min TTO was assigned as >120 min [27] .
2.5. FeCl 3 induced thrombosis in mice mesenteric artery using intravital microscopy 2.5.
Preparation of platelets
Blood was isolated from anesthetized mice and diluted with tri sodium citrate (2.5% w/v, pH 6.4) in 1:9 ratio. Platelet-richplasma (PRP) was obtained by centrifugation at 100Âg for 5 min. The PRP and buffy coat containing some RBCs was gently transferred to fresh polypropylene tubes and re-centrifuged at 100Âg for 5 min. PRP was incubated with prostaglandin I 2 (PGI 2 , 20 ng/mL) at 37°C for 5 min. PRP was further centrifuged at 600Âg for 5 min and pellet obtained was resuspended in 1 mL modified Tyrode's-HEPES buffer (137 mM NaCl, 0.3 mM Na 2 HPO4, 2 mM KCl, 12 mM NaHCO 3 , 5 mM HEPES, 5 mM glucose, 0.35% BSA, pH 7.2) containing PGI 2 (20 ng/mL) for 5 min at 37°C. Platelets were washed twice and finally resuspended in modified Tyrode's-HEPES buffer and was fluorescently labelled with calcein red-orange, AM (2.5 mg/mL) for 20 min at room temperature.
Intravital microscopy
FITC-labelled Dextran (2 mg/mice) and calcein red orange labelled platelets (1.25 Â 10 9 /kg) were injected through retroorbital plexus to visualize the blood vessels and platelets respectively as described before. An incision was made through abdominal wall, mesenteric artery was exposed and Whatmann filter paper (2 mm Â 0.5 mm) saturated with 10% FeCl 3 solution was applied topically for 3 min and then removed. Thrombus formation was monitored in real time under fluorescent microscope [Olympus FV1200 (BX61Wi), Japan] coupled to a charge-coupled device (CCD) camera. Time to vascular occlusion by thrombus was determined. The end point of the experiment was recorded when blood flow has completely stopped or 40 min in case occlusion is not observed. Blood flow velocity was calculated as the displacement of the fluorescently labelled platelets between two consecutive frames divided by the time delay between the two captures using Image J software [28] [29] [30] .
Liver and spleen hemorrhagic model
The liver and spleen were exposed via a midline incision. A paraffin film was placed under the left anterior liver lobe. After incision, filter paper pieces (4-5 mm long and 3-4 mm wide) were placed over cut surface at 5 s interval until complete cessation. The bleeding time was taken as the total time elapsed between the incision and the end point. Similarly filter paper pieces were placed over cut surface of spleen until the end point was reached, and total time was recorded as described previously [31] [32] [33] .
Ex vivo studies 2.7.1. Blood collection and platelet isolation
Blood was drawn by cardiac puncture from anaesthetized mice and mixed with 2.5% tri-sodium citrate. Platelet-rich plasma (PRP) was obtained by centrifugation at 180Âg for 20 min at room temperature. Washed platelets were prepared as described in Section 2.5.1 [34] .
Platelet adhesion and aggregation
Glass cover slips were coated with equine tendon native fibrillar type I collagen (Chrono-par, Chrono-log Corp., USA), and subsequently blocked with 5 mg/ml BSA at room temperature for 1 h, and finally washed once with PBS. Human or murine platelets, were added to the cover slips (10 7 /well) for 1 h [16] . After washing thrice, the adhered platelets were fixed with 2% paraformaldehyde for 15 min and then stained for 1 h with phalloidin-TRITC. Platelets were viewed on a fluorescent microscope (Leica FW 4000) at 40Â magnification. The fluorescence images were recorded from at least five different microscope fields and the results are expressed as average number of cells adhered for all the areas [35] .
Platelet aggregation was performed using a four channelaggregometer (Chronolog-corp, Havertown, USA). Murine platelet rich plasma (1 Â 10 8 platelets/ml, 0.45 mL) was pre-warmed to 37°C for 2 min before addition of various agonists [2 lg/ml Collagen (Chrono-log, Corp.), 10 lM ADP (Sigma), 0.25 mM Arachidonic
Acid (Chrono-log Corp)]. The reactions were allowed to proceed for at least 5 min, and the extent of aggregation was expressed in light-transmission units using Aggrolink software [22] .
In vitro studies 2.8.1. Blood collection and platelet isolation
The present study was approved by the Institutional Ethics committee of CSIR-CDRI, Lucknow, India and King George Medical University, Lucknow, India. The study has conformed to the guidelines of Helsinki Declaration. Blood was drawn by venipuncture from healthy human volunteers in citrate-phosphate-dextrose or PPACK (for whole blood perfusion assay). All donors have provided their written informed consent. Dimethyl sulfoxide (DMSO) was used to dissolve S007-867 and hence it was used at the final concentration (0.1-0.4%) as vehicle/solvent in all experiments.
Whole blood perfusion assay
Whole blood was incubated with 3, 3 0 dihexyloxacarbocyanine iodide (DiOC6, 1 mM) for 15 min and the perfusion studies were performed as described earlier [36, 37] . Glass coverslips were coated with collagen or other peptides overnight at 4°C, and blocked with 1% BSA. The coverslip, in a 125 mm-deep flow chamber, was mounted on an FV300 laser-scanning confocal microscope (Olympus) and washed for 1 min with HEPES buffer containing 100 U/mL heparin. Blood was drawn through the chamber for 5 min using a syringe pump at a wall shear rate of 1000 s À1 .
Coagulation parameters
Coagulation parameters, prothrombin time, activated partial thromboplastin time (aPTT) and thrombin time (TT) were measured in plasma as per manufacturer's instructions using a Semi automated Coagulometer (Start4, Young Instruments, Stago, France) [38] .
Intracellular calcium mobilization
Platelet rich plasma (PRP) was incubated with 5 lM Fura-2 AM for 60 min at 37°C. After washing, the Fura-2 fluorescence was measured in collagen stimulated platelets at an excitation wavelength of 340/380 nm and emission wavelength of 500 nm using a fluorescence spectrophotometer (VARIAN, Cary Eclipse) [34] .
ATP release
ATP secretion was monitored in platelet rich plasma by adding Chronolume reagent (Chronolog). The luminescence generated by platelets upon collagen stimulation was compared with an ATP standard as reported earlier [16] .
2.8.6. Thromboxane A 2 generation
As described previously, washed platelets were stimulated with collagen for 5 min at 37°C, and the reaction was terminated by addition of ice-cold EDTA solution (10 mM) containing 10 mM indomethacin. The samples were centrifuged and thromboxane B 2 (TxB 2 ), the stable metabolite of TxA 2 , was measured using a correlate-EIA thromboxane B 2 kit [34] .
Immunoprecipitation
Washed platelets were lysed in radio immuno precipitation assay (RIPA) buffer [PBS containing 0.1% SDS, 0.5% sodium deoxycholate, 1% Triton X-100, and protease inhibitors cocktail] for 15 min. The supernatant was pre-cleared with protein A/G agarose (Amersham biosciences, Upsala, Sweden) and incubated with 1 lg of primary antibody (PLCc2). After 2 h, 20 ll of protein A/G agarose was added and incubated for 1 h. The beads were washed, re-suspended in Laemmli buffer, denatured at 95°C for 5 min, and subsequently analyzed by immunoblotting [34, 38] .
Immunoblotting
Platelets were stimulated with collagen, and the reaction was stopped by adding 4Â Laemmli buffer [39] (containing 10 lg/ml aprotinin, 1 mM PMSF, 10 lg/ml leupeptin, 10 mM NaF, 1 mM sodium orthovanadate). The lysates were boiled for 3 min [34, 38] , and centrifuged at 12,000Âg for 5 min. Samples containing 30-40 lg of protein were subjected to SDS-PAGE and immunoblotting as described previously [34, 38] .
Statistical analysis
Graph Pad Prism 5.0 (Graph Pad Inc., La Jolla, CA, USA) was used for statistical analysis. All the results are expressed as the mean ± standard deviation (SD). Student's t-test or one-way ANOVA followed by posthoc test was used and P values less than .05 were considered significant.
Results
3.1.
In vivo studies 3.1.1. Effect of S007-867 on arterio-venous shunt model in rats
When compared to vehicle, S007-867 significantly reduced wet thrombus weight from 51.2 ± 12 mg to 31.2 ± 2.5 mg, 31.2 ± 7.2 mg, and 30.5 ± 8.7 mg at doses of 10, 30, and 100 lmol/kg respectively (Fig. 1A) . Both aspirin and clopidogrel significantly reduced thrombus weight (25.4 ± 3.3 mg, 24 ± 3.3 mg respectively) in comparison to vehicle (Fig. 1A) . 1B shows that in vehicle-treated mice, FeCl 3 application led to complete occlusion of blood flow at 14 ± 0.2 min, which was significantly prolonged to 20.2 ± 2 min (1.3 ± 0.1 fold) in mice pretreated with clopidogrel. S007-867 (30, 100 & 300 mmol/kg) dose dependently prolonged the time to occlusion with significant elevation at 100 & 300 mmol/kg. It significantly delayed the growth of thrombi by 1.18 ± 0.2 and 1.25 ± 0.08 fold at 100 and 300 mmol/kg respectively in comparison to vehicle treated mice. Aspirin displayed no significant antithrombotic protection in this model (Fig. 1B) .
Effect of S007-867 on bleeding time in mice
In vehicle treated mice, bleeding stopped after 3.5 ± 0.7 min and 4.9 ± 1.2 min in liver (Fig. 1C) and spleen (Fig. 1D) injury model respectively. Clopidogrel showed significant increase in bleeding in spleen (8.2 ± 0.6 min), while there was no significant alteration in bleeding time in liver (3.0 ± 0.8 min) in mice. Animals treated with aspirin (liver: 3.1 ± 0.6 min; spleen: 5.9 ± 1.8 min) or S007-867 (liver: 3.6 ± 1.2 min; spleen: 5.5 ± 1.9 min) did not show significant alteration in either of the injury models in comparison to vehicle treated mice (Fig. 1C and D) .
Effect of S007-867 on ferric chloride-induced thrombosis in mesenteric artery in mice
We further performed time-lapse analysis to reveal any changes in kinetics of thrombus formation after administration of S007-867 (30 mmol/kg) under in vivo settings. Topical application of 10% FeCl 3 on mesenteric artery initiated thrombi formation within 3 min in vehicle treated mice (Fig. 2B, Video 1) . The thrombi formed in S007-867 treated mice were initially smaller as compared to vehicle treated mice. Moreover the growth of thrombi was slower in S007-867 treated mice, while thrombi grew faster in vehicle treated mice. The blood flow velocity continuously decreased in control mice with complete cessation of blood flow at around 20 min whereas in S007-867 treated mice blood flow velocity was sustained even after 30 min of FeCl 3 injury (Fig. 2C, Video 2) . Complete cessation of blood flow in vehicle treated mice was seen at an average vessel occlusion time of 21.2 ± 6.2 min, while S007-867 treated mice exhibited an average time to occlusion of 42.13 ± 10.3 min (Fig. 2A) . Thus, the compound S007-867 was able to delay the progression of thrombi and the time to occlusion as compared to control mice with sustained maintenance of vessel blood flow velocity. 
Effect of S007-867 on collagen mediated platelet adhesion and aggregation in mice (ex vivo)
The aggregation profile of S007-867 in mice platelets exhibited significant reduction in collagen induced platelet aggregation in a dose dependent manner (Fig. 3A) . The mean percent aggregation following collagen stimulation at 30 mmol/kg is 32 ± 1.1% which was further reduced to 9.8 ± 9% at 100 mmol/kg and 2.8 ± 2.7% at 300 mmol/kg. The ADP-and arachidonic acid-mediated platelet responses remained unaltered, thus confirming the anti-platelet mode of action of the compound to be mediated via collagen receptor (Fig. 3A) . S007-867 also evoked significant inhibition in platelet adhesion over collagen in a dose dependent manner (53.87 ± 17% at 30 mmol/kg, 65.1 ± 11.3% at 100 mmol/kg and 79.2 ± 8.6% at 300 mmol/kg) (Fig. 3B, C) . Clopidogrel (100 mmol/kg) also showed significant inhibition in the number of platelets adhered over collagen (67.3 ± 7.4%), while Aspirin (100 mmol/kg) did not show any effect.
In vitro studies
Effect of S007-867 on whole blood perfusion assay
Whole blood treated with S007-867 at a concentration of 100 mM, did not show any inhibitory effect on surface coverage (indicating platelet adhesion), when perfused over collagen or other collagen mimetic peptides (Fig. 4A, B) . However S007-867 significantly reduced mean thrombus volume or ZV 50 over CRP-GFOGER-VWF-III (CGV) surface from 3.7 ± 0.38 mm to 1.7 ± 0.17 mm (Fig. 4C, D) . S007-867 did not affect ZV 50 on collagen, CRP-GFOGER or GFOGER-VWF-III surfaces. ZV 50 measures the height of the centre of mass of thrombus. The height of the thrombus indicates build-up of thrombi due to platelet-platelet interaction and hence is considered to be a more direct measure of platelet activation.
Effect of S007-867 on coagulation parameters in human plasma
No change was observed in Thrombin Time (TT), Prothrombin Time [21] , and activated Partial Thromboplastin Time (aPTT) when compared to their isovolumetric vehicle control. Hirudin, a standard anticoagulant, significantly increased TT, PT and aPTT (Fig. 5A-C) .
Effect of S007-867 on collagen induced intra-platelet calcium flux
Addition of collagen to human platelet suspension in the presence of 1 mM CaCl 2 resulted in an increase in [Ca 2+ ] i (Fig. 5D) (Fig. 5D, E ).
Effect of S007-867 on collagen induced ATP release from platelets
The compound S007-867 attenuated collagen induced ATP release from platelets in a concentration-dependent manner. The vehicle (DMSO) treated platelets released 4.6 ± 0.14 nm of ATP, which was significantly reduced to 1.9 ± 0.2 nm (55 ± 10.8%) and 1.6 ± 0.1 nm (63.1 ± 5.4%) by S007-867 at concentrations 30 and 100 mM respectively (Fig. 5F ). It showed maximum inhibition in ATP release at 300 mM (80.5 ± 6.8%).
Effect of S007-867 on thromboxane A 2 generation from platelets
S007-867 exhibited 30 ± 10% and 56 ± 36% inhibition in TxB 2 levels at 30 mM and 100 mM respectively. Aspirin also displayed a concentration dependent inhibition in TxB 2 release with mean maximal inhibition of 48.4 ± 28% at 100 mM. Apparently the inhibitory potential of S007-867 was almost comparable to that of COX inhibitor Aspirin (Fig. 5G ).
Effect of S007-867 on collagen induced tyrosine phosphorylation of platelet proteins
The activation of platelets by collagen contributes to the assembly and stabilization of various signalling complexes. When treated with S007-867 at various concentrations (10-300 mM), the phosphorylated levels of a number of proteins were decreased compared to vehicle control. As shown in Fig. 5H , S007-867 exhibited concentration-dependent reduction in the phosphorylation levels of proteins lying approximately in the molecular weight range of 100-130 kDa, 75-90 kDa, 45-60 kDa. Furthermore, S007-867 inhibited the phosphorylation of platelet PLCc-2 in a concentration-dependent manner with a significant effect at 300 mM (Fig. 5I) , thereby implicating that the compound disrupts platelet function via modulation of collagen induced signalling cascade.
Discussion
Platelet collagen interaction is a critical phenomenon underlying thrombosis. Blocking collagen induced platelet activation to prevent thrombosis is anticipated to be safer and efficacious, either alone or in combination with existing drugs. In a previous study, we have identified S007-867 as a novel synthetic antithrombotic compound that specifically inhibits collagen-induced platelet aggregation. The present study describes the pre-clinical pharmacological profile of S007-867 in detail in animal and in vitro models of thrombosis. S007-867 (30 lmol/kg) in mice displayed a remarkable antithrombotic efficacy with minimal impact on tail bleeding time, in comparison to aspirin and clopidogrel [22] . In the present study, S007-867 showed significant reduction in thrombus weight even at a low dose of 10 lmol/kg in rat model of arterio venous shunt.
The thrombus in arterio-venous shunt model closely mimics arterial thrombus and is mainly composed of platelets and fibrin [40] . The antithrombotic efficacy of S007-867 was comparable to that of standard drug aspirin and clopidogrel in minimizing thrombosis.
Another model used in the present study is ferric chloride induced arterial injury, which is routinely used for pre-clinical testing of antithrombotic compounds, either using a Doppler flow probe to record time of vessel occlusion, or using intravital microscopy to directly visualize thrombosed blood vessels in vivo. We have used both techniques to assess antithrombotic efficacy of S007-867 in mice. Using Doppler flow probe in carotid artery, we observed that S007-867 and clopidogrel significantly prolonged the time to occlusion (TTO), while aspirin did not show any protective effects. Collagen Type I is exposed following endothelial injury due to ferric chloride and has been visualized in vivo using anti-collagen antibodies [41] . Our results are in agreement with previous study that showed reduced thrombus formation in the absence or blocking of platelet collagen receptor GPVI indicating a significant participation of platelet collagen interaction in this model [42] . Intravital microscopy has been routinely used to study the progression and mechanisms of thrombosis in vivo in real time, and is a highly useful technique to check the validity of in vitro or ex vivo experimental observations in live animals. We observed that platelet deposition and the onset of thrombus formation in mesenteric artery were delayed in S007-867 treated mice in comparison to control. None of the S007-867 treated mice showed blood flow cessation within 30 min. Thus, S007-867 significantly maintained the blood flow velocity for a longer duration and delayed vessel occlusion.
Perioperative bleeding episodes is one of the major concerns with the use of current anticoagulants and anti-platelet drugs. An ideal antithrombotic agent is anticipated to maintain an appropriate balance between hemostasis and thrombosis. Screening antithrombotic test compounds in different bleeding models can be a good predictor of its hemorrhagic potential, because vascular beds in different organs vary in their structural composition, local tissue factor generation and other surface-dependent processes at the site of injury. We evaluated S007-867 in liver and spleen hemorrhagic model at its efficacy dose (30 mmol/kg). The bleeding time was not significantly altered in either aspirin or S007-867 treated mice, while clopidogrel showed significant increase in spleen bleeding time. Therefore, S007-867 might offer some improvement with respect to the critical disadvantage of bleeding encountered with current antithrombotics. Additionally, owing to its minimal impact on hemostasis, it may be further tested in combination with standard anti-platelet drug (like aspirin) and anticoagulants.
Previous studies from our lab showed that S007-867 specifically inhibited collagen induced platelet aggregation in human plasma (IC 50 = 6 mM), while other platelet activation pathways remained unhindered [22] . However its effect on the coagulation cascade is not known. The present study confirmed that the mode of action of S007-867 is platelet-mediated, as it did not exhibit any effect on either the extrinsic or intrinsic coagulation cascade in plasma even at very high concentrations. Following endothelial injury or atherosclerotic plaque rupture, collagens I and III are the predominant species exposed to the circulating platelets. The multiple collagen receptors on platelet surface act in tight synergy with each other to initiate platelet adhesion and thrombus formation. Platelets are transiently attached to collagen via VWF and its receptor-GP1b/IX/V. This interaction is further strengthened by platelet integrin a 2 b 1 , which arrests platelet rolling and also co-operate with platelet GPVI to bind collagen, finally resulting in firm platelet adhesion and thrombus growth [43] . Our major finding in ferric chloride induced thrombosis model was sustained maintenance of blood flow velocity in S007-867 treated mice. This observation was further corroborated by whole blood perfusion assay over collagen and collagenmimetic peptides, CRP, GFOGER and vWF-III. We performed whole blood perfusion assay with an aim to resolve the discrepancy with respect to specific collagen receptor being targeted by S007-867. Specific peptides and their combinations are useful in defining the individual role of platelet collagen receptors during thrombus formation. S007-867 did not show inhibition in thrombus formation when blood was perfused over VWF-III or a mixture of VWF-III and GFOGER, thereby ruling out GP1b/IX/V or a 2 b 1 as the main target of S007-867. It is noteworthy that S007-867 did not inhibit primary platelet adhesion as evidenced by its minimal inhibitory effect on surface coverage or thrombus volume over either collagen or combination of peptides. Interestingly the compound showed significant inhibition of thrombus volume (ZV 50 ) formed over a mixture of CRP, GFOGER and VWF-III peptide coated surfaces. This effect was seen as a striking change in thrombus morphology, with abundant but much smaller thrombi remaining. Since ZV 50 is an indicator of thrombus height defined by plateletplatelet interaction and hence denotes the extent of platelet activation, it is assumed that S007-867 might be acting by either inhibiting GPVI receptor activation or its immediate downstream signalling pathways. However, with strong agonists like polymeric collagen and CRP, weak inhibition was observed with S007-867 suggesting that strong stimulation of GPVI activation/signalling pathway can survive blockade by S007-867 and promotes good adhesion or activation.
Interestingly, the pharmacologically effective concentrations to inhibit in vitro platelet adhesion and activation are high (ranging from 30 to 300 lM), while the same compound showed low effective dose in animal models (30 mmol/kg) and low IC 50 in plasma [22] . Previous study regarding pharmacokinetic assessment in mice has shown that S007-867 is rapidly absorbed after oral dosing, and hence exhibits fast onset of action [24] . S007-867 at a dose of 30 lmol/kg ($13 mg/kg) achieved maximal plasma concentration (C max ) up to 1823.33 ng/mL within 15 min in mice [24] , and showed significant antithrombotic efficacy in mice at such low concentration detected in plasma. However, S007-867 owing to its low log P value, is a highly hydrophobic compound. Since most of the in vitro experimental assays rely upon the use of aqueous buffers which may induce precipitation or incomplete binding of hydrophobic compounds during the course of an experiment. Hence presumably S007-867 is required in high concentrations (30-300 mM) and showed high IC 50 when used in buffers to effectively inhibit collagen induced platelet activation. Although the accurate assessment of its in vitro potency against platelet activation was somewhat difficult owing to its high hydrophobicity, the present study shows that S007-867 specifically inhibits collagen induced platelet activation in a concentration dependent manner. Collagen strongly activates intra-platelet signalling events, which can be assessed by mapping global protein tyrosine phosphorylation. Upon collagen stimulation, platelet Syk undergoes autophosphorylation and binds to immunoreceptor tyrosine based activation motif (ITAM) of FcR-c. This initiates downstream signalling via PLCc-2 and generates second messenger inositol 1,4,5-trisphosphate and DAG. Intra-platelet [Ca 2+ ] i is increased and other signalling pathways are activated. S007-867 inhibits tyrosine phosphorylation of many proteins including PLCc-2. Furthermore it also blocked intra-platelet [Ca 2+ ] flux, ATP release from platelet granules and thromboxane A 2 generation via COX-1 activation.
In conclusion, the present study using in vivo experimental models in rats and mice, confirms that S007-867 inhibits arterial thrombosis and delays vessel occlusion time by inhibiting collagen induced platelet activation. It significantly inhibits collagen mediated platelet activation and subsequently reduced the release of ATP from dense granules and thromboxane A 2 via COX1 activation. S007-867 also inhibits collagen induced calcium flux and tyrosine phosphorylation of various proteins including PLCc2. S007-867, being an orally active synthetic compound did not induce or promote bleeding, and hence offers better benefit to risk balance in pre-clinical screening and efficacy models. Therefore, S007-867 may be further developed and clinically deployed for the treatment of coronary and cerebral artery diseases. 
